Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Background: Novel treatment approaches including chimeric antigen receptor (CAR) T therapy and bispecific antibodies (Abs) have shown remarkable efficacy in highly pretreated multiple myeloma (MM) patients. With recent approval of BCMA-targeted CAR T in MM, and other agents in development, CAR T is poised to become more widely used in relapsed/refractory disease (RRMM). However, the prognosis, clinical outcome, and treatment approach to RRMM patients presenting with relapsed disease after CAR T are unknown.